Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Dec 24

PMID 34944738

Citations 9

Authors

Farhana Mollah

Pegah Varamini

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most diagnosed cancer and is the leading cause of cancer mortality in women. Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Often, TNBC is not effectively treated due to the lack of specificity of conventional therapies and results in relapse and metastasis. Breast cancer-associated fibroblasts (BCAFs) are the predominant cells that reside in the tumor microenvironment (TME) and regulate tumorigenesis, progression and metastasis, and therapy resistance. BCAFs secrete a wide range of factors, including growth factors, chemokines, and cytokines, some of which have been proved to lead to a poor prognosis and clinical outcomes. This TME component has been emerging as a promising target due to its crucial role in cancer progression and chemotherapy resistance. A number of therapeutic candidates are designed to effectively target BCAFs with a focus on their tumor-promoting properties and tumor immune response. This review explores various agents targeting BCAFs in TNBC, including small molecules, nucleic acid-based agents, antibodies, proteins, and finally, nanoparticles.

Citing Articles

ANO10 is a potential prognostic biomarker and correlates with immune infiltration in breast cancer.

Ning R, Pan S, Xiao D, Zheng Y, Zhang J Am J Cancer Res. 2023; 13(5):1845-1862.

PMID: 37293146 PMC: 10244099.

Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.

Mani C, Acharya G, Saamarthy K, Ochola D, Mereddy S, Pruitt K Breast Cancer Res. 2023; 25(1):44.

PMID: 37081516 PMC: 10120249. DOI: 10.1186/s13058-023-01615-6.

microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer.

Funamizu N, Honjo M, Tamura K, Sakamoto K, Ogawa K, Takada Y Cancers (Basel). 2023; 15(4).

PMID: 36831572 PMC: 9953943. DOI: 10.3390/cancers15041230.

Special Issue: Resistance to Targeted Therapies in Human Cancer.

Lee T, Choi H, Lee K, Lee J Biomedicines. 2023; 11(2).

PMID: 36830950 PMC: 9953462. DOI: 10.3390/biomedicines11020414.

The application of exosomes in the treatment of triple-negative breast cancer.

Weaver J, Zhang J, Rojas J, Musich P, Yao Z, Jiang Y Front Mol Biosci. 2022; 9:1022725.

PMID: 36438660 PMC: 9684310. DOI: 10.3389/fmolb.2022.1022725.

References

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T . Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget. 2017; 8(15):24506-24517. PMC: 5421866. DOI: 10.18632/oncotarget.15534. View

Martin A, Tomasin R, Luna-Dulcey L, Graminha A, Naves M, Teles R . [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models. Cell Oncol (Dordr). 2020; 43(5):915-929. DOI: 10.1007/s13402-020-00539-z. View

Bayer S, Grither W, Brenot A, Hwang P, Barcus C, Ernst M . DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFs. Elife. 2019; 8. PMC: 6555593. DOI: 10.7554/eLife.45508. View

Kaur H, Bruno J, Kumar A, Sharma T . Aptamers in the Therapeutics and Diagnostics Pipelines. Theranostics. 2018; 8(15):4016-4032. PMC: 6096388. DOI: 10.7150/thno.25958. View

Yang X, Zhao L, Zheng L, Xu M, Cai X . Polyglycerol grafting and RGD peptide conjugation on MnO nanoclusters for enhanced colloidal stability, selective cellular uptake and cytotoxicity. Colloids Surf B Biointerfaces. 2018; 163:167-174. DOI: 10.1016/j.colsurfb.2017.12.034. View

Barata P, Sood A, Hong D . RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016; 50:35-47. DOI: 10.1016/j.ctrv.2016.08.004. View

Aboulkheyr Es H, Zhand S, Thiery J, Warkiani M . Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb). 2020; 12(7):188-197. DOI: 10.1093/intbio/zyaa014. View

Hassan R, Alewine C, Pastan I . New Life for Immunotoxin Cancer Therapy. Clin Cancer Res. 2015; 22(5):1055-8. PMC: 4775389. DOI: 10.1158/1078-0432.CCR-15-1623. View

10.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

11.

Ren Y, Zhou X, Yang J, Liu X, Zhao X, Wang Q . AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis. Cancer Lett. 2015; 362(2):174-82. DOI: 10.1016/j.canlet.2015.03.038. View

12.

Li Q, Li M, Zheng K, Tang S, Ma S . Expression pattern analysis and drug differential sensitivity of cancer-associated fibroblasts in triple-negative breast cancer. Transl Oncol. 2020; 14(1):100891. PMC: 7563008. DOI: 10.1016/j.tranon.2020.100891. View

13.

Mishra R, Haldar S, Suchanti S, Bhowmick N . Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. Endocr Relat Cancer. 2019; 26(12):R673-R688. PMC: 6859444. DOI: 10.1530/ERC-19-0347. View

14.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

15.

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

16.

Camorani S, Hill B, Fontanella R, Greco A, Gramanzini M, Auletta L . Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer. Theranostics. 2017; 7(14):3595-3607. PMC: 5596446. DOI: 10.7150/thno.18974. View

17.

Arcucci A, Ruocco M, Granato G, Sacco A, Montagnani S . Cancer: An Oxidative Crosstalk between Solid Tumor Cells and Cancer Associated Fibroblasts. Biomed Res Int. 2016; 2016:4502846. PMC: 4993917. DOI: 10.1155/2016/4502846. View

18.

Furuuchi K, Rybinski K, Fulmer J, Moriyama T, Drozdowski B, Soto A . Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models. Cancer Sci. 2021; 112(6):2467-2480. PMC: 8177789. DOI: 10.1111/cas.14898. View

19.

Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K . Fibroblasts in the Tumor Microenvironment: Shield or Spear?. Int J Mol Sci. 2018; 19(5). PMC: 5983719. DOI: 10.3390/ijms19051532. View

20.

Hendrayani S, Al-Khalaf H, Aboussekhra A . Curcumin triggers p16-dependent senescence in active breast cancer-associated fibroblasts and suppresses their paracrine procarcinogenic effects. Neoplasia. 2013; 15(6):631-40. PMC: 3664995. DOI: 10.1593/neo.13478. View